Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, shares some insights into a study investigating the use of tagraxofusp, a recently approved CD123-targeted therapy, for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Receiving grant support, paid to GWT-TUD, from Amgen, lecture fees, grant support, paid to the University of Leipzig, fees for serving on a steering committee, consulting fees, and travel support from Celgene, grant support, paid to GWT-TUD, from Janssen Biotech, grant support, paid to University Dresden, from Merck and Novartis, and lecture fees from Novartis.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.